Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics. Its key marketed product is JAKAFI, used to treat myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. The company also offers ICLUSIG for certain leukemias, MONJUVI/MINJUVI for diffuse large B-cell lymphoma and follicular lymphoma, NIKTIMVO for chronic graft-versus-host disease, PEMAZYRE for biliary tract cancer and other conditions, and ZYNYZ for Merkel cell carcinoma. Incyte's pipeline includes candidates like INCA033989 for essential thrombocythemia, INCB123667 for ovarian cancer, and ruxolitinib cream for atopic dermatitis and hidradenitis suppurativa. The company operates in the United States, Europe, Canada, and Japan.

Incyte Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol INCY. Its shares are traded in US Dollars (USD). The company is headquartered in the United States and is part of the US region.

Incyte Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on discovering, developing, and commercializing innovative therapies for serious diseases, primarily in oncology and inflammatory conditions. Its products target conditions such as myelofibrosis, leukemia, lymphoma, and graft-versus-host disease.

Incyte Corporation's operations span the United States, Europe, Canada, and Japan. The company is headquartered in the United States and markets its approved therapeutics across these regions. Its global presence allows it to serve patients with various cancers and inflammatory diseases through its portfolio of marketed drugs and clinical-stage candidates.

Incyte's portfolio includes several marketed drugs: JAKAFI (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; ICLUSIG (ponatinib) for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI (tafasitamab) for diffuse large B-cell lymphoma and follicular lymphoma; NIKTIMVO (axatilimab) for chronic graft-versus-host disease; PEMAZYRE (pemigatinib) for biliary tract cancer and myeloid/lymphoid neoplasms; and ZYNYZ (retifanlimab) for Merkel cell carcinoma. The pipeline includes INCA033989 for essential thrombocythemia, INCB123667 for ovarian cancer, and ruxolitinib cream for atopic dermatitis and hidradenitis suppurativa.